Antibiotics and outcomes of CF pulmonary exacerbations in children infected with MRSA and Pseudomonas aeruginosa.

[1]  L. Hoffman,et al.  Clinical Outcomes of Antipseudomonal versus Other Antibiotics Among Children with Cystic Fibrosis without Pseudomonas aeruginosa. , 2022, Annals of the American Thoracic Society.

[2]  L. Hoffman,et al.  Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  M. Mei-Zahav,et al.  Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis-data from the European cystic fibrosis society patient registry. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[4]  L. Saiman,et al.  Finding the relevance of antimicrobial stewardship for cystic fibrosis. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[5]  M. Hall,et al.  Evaluation of hospitalization data for the CFFPR‐PHIS linked data set , 2020, Pediatric pulmonology.

[6]  W. Morgan,et al.  Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis , 2019, Pediatric pulmonology.

[7]  Jessica M Franklin,et al.  Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners , 2019, BMJ.

[8]  G. Sawicki,et al.  Linkage of the CF foundation patient registry with the pediatric health information system database , 2019, Pediatric pulmonology.

[9]  D. Görlich,et al.  Staphylococcus aureus in the airways of cystic fibrosis patients - A retrospective long-term study. , 2018, International journal of medical microbiology : IJMM.

[10]  M. Muhlebach.  Methicillin-resistant Staphylococcus aureus in cystic fibrosis: how should it be managed? , 2017, Current opinion in pulmonary medicine.

[11]  Joshua D. Courter,et al.  Accuracy of Administrative Data for Antimicrobial Administration in Hospitalized Children , 2017, Journal of the Pediatric Infectious Diseases Society.

[12]  O. Dekkers,et al.  Control of confounding in the analysis phase – an overview for clinicians , 2017, Clinical epidemiology.

[13]  L. Hoffman,et al.  Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations , 2017, Pediatrics.

[14]  Aliza K Fink,et al.  The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry. , 2016, Annals of the American Thoracic Society.

[15]  N. McCarty,et al.  A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study. , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[16]  J. Goldberg,et al.  Staphylococcus aureus and Pseudomonas aeruginosa co-infection is associated with cystic fibrosis-related diabetes and poor clinical outcomes , 2016, European Journal of Clinical Microbiology & Infectious Diseases.

[17]  P. Burgel,et al.  Association between Staphylococcus aureus alone or combined with Pseudomonas aeruginosa and the clinical condition of patients with cystic fibrosis. , 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[18]  S. Stanojevic,et al.  Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis , 2011, European Respiratory Journal.

[19]  N. Høiby.  Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis , 2011, BMC medicine.

[20]  Margaret Rosenfeld,et al.  Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. , 2010, American journal of respiratory and critical care medicine.

[21]  C. Merlo,et al.  Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. , 2010, JAMA.

[22]  Karen A Robinson,et al.  Pulmonary Perspective Cystic Fibrosis Pulmonary Guidelines Treatment of Pulmonary Exacerbations , 2009 .

[23]  G. Sawicki,et al.  The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis , 2008, Pediatric pulmonology.

[24]  C. Merlo,et al.  Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. , 2008, American journal of respiratory and critical care medicine.

[25]  C. Goss,et al.  Exacerbations in cystic fibrosis · 1: Epidemiology and pathogenesis , 2007, Thorax.

[26]  M. Rosenfeld,et al.  Cystic fibrosis pulmonary exacerbations. , 2006, The Journal of pediatrics.

[27]  J. Emerson,et al.  Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis , 2002, Pediatric pulmonology.

[28]  M. Ballmann,et al.  Long term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosacolonisation in patients with cystic fibrosis , 1998, Thorax.

[29]  R. Hornung,et al.  Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. , 2002, Chest.